First generic development of new antithrombotic drug, ‘Brilinta,’ has begun
Movements to develop the first generic of the AstraZeneca’s next-generation antithrombotic drug, Brilinta(generic name: ticagrelor), have been observed.
On the 14th, the Ministry of Food and Drug Safety approved bioequivalence tests of ticagrelor 90mg applied by Binex, a biopharmaceutical ventur...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
